Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.40
KBIO's Cash-to-Debt is ranked lower than
85% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. KBIO: 0.40 )
Ranked among companies with meaningful Cash-to-Debt only.
KBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 6.63 Max: No Debt
Current: 0.4
Piotroski F-Score: 1
Altman Z-Score: -71.99
Beneish M-Score: -2.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA % -360.61
KBIO's ROA % is ranked lower than
96% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. KBIO: -360.61 )
Ranked among companies with meaningful ROA % only.
KBIO' s ROA % Range Over the Past 10 Years
Min: -360.61  Med: -94.2 Max: -23.07
Current: -360.61
-360.61
-23.07
ROC (Joel Greenblatt) % -23984.74
KBIO's ROC (Joel Greenblatt) % is ranked lower than
80% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. KBIO: -23984.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23984.74  Med: -4846.14 Max: -1045.43
Current: -23984.74
-23984.74
-1045.43
3-Year Revenue Growth Rate -100.00
KBIO's 3-Year Revenue Growth Rate is ranked lower than
100% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. KBIO: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KBIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: -94.4
Current: -100
3-Year EBITDA Growth Rate -40.90
KBIO's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. KBIO: -40.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KBIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.9 Max: 9.4
Current: -40.9
0
9.4
3-Year EPS without NRI Growth Rate -41.40
KBIO's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. KBIO: -41.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
KBIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.4 Max: 0.1
Current: -41.4
0
0.1
GuruFocus has detected 3 Warning Signs with KaloBios Pharmaceuticals Inc $KBIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KBIO's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with KBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:THLD, NAS:BVXV, NAS:ONS, OTCPK:NWBO, NAS:CYTX, NAS:NVUS, AMEX:IBIO, NAS:NEOT, NAS:OHRP, OTCPK:USRM, NAS:PLXP, NAS:EBIO, OTCPK:CVALF, NAS:TPIV, NAS:AZRX, NAS:ADHD, OTCPK:VBIO, NAS:NVLS, NAS:VKTX, NAS:CHMA » details
Traded in other countries:0KB1.Germany,
Headquarter Location:USA
KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development of monoclonal antibody therapeutics for rare diseases.

KaloBios Pharmaceuticals Inc. was incorporated on March 15, 2000. On February 5, 2013 the Company closed its initial public offering. The Company is a biopharmaceutical company engaged on the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families. With Humaneered antibody technology, the Company produced a portfolio of patient-targeted, first-in-class, antibodies to treat serious medical conditions with a clinical focus on respiratory diseases and cancer. Humaneered antibodies have tested clinically in over 250 patients with no evidence of immunogenicity. The Company identifies and develops products that treat multiple indications through proof-of-concept studies. The Company has advanced three antibodies to the clinical development stage: KB001-A, for the treatment of Pa VAP; KB004, for hematologic malignancies; and KB003, for severe asthma. KB001-A, is a Humaneered, recombinant, PEGylated, anti-Pseudomonas PcrV high-affinity Fab antibody that is being developed for the prevention and treatment of infections by Pa, a gram negative bacteria that can cause pneumonia in mechanically ventilated patients and chronic respiratory infections in individuals with CF. KB004 is a Humaneered, monoclonal antibody in which the carbohydrate chains lack fucose, thereby enhancing the targeted cell-killing activity of the antibody. KB003 is a Humaneered, recombinant monoclonal antibody that targets and neutralizes human granulocyte macrophage colony-stimulating factor, or GM-CSF, with potential for use in inflammatory, autoimmune and other indications. Humaneered technology platform addresses issues of therapeutic antibody engineering and down-stream processing issues. The Humaneered technology is a method for converting antibodies into engineered human antibodies designed for therapeutic use, particularly for chronic conditions. The technology is designed to produce antibodies that have specificity and affinity for their target antigen, low propensity for aggregation, and a long-term stability. KB001-A, KB003, and KB004 are all Humaneered antibodies or antibody fragments. The Company currently has a collaboration with Sanofi for the development of KB001-A, and have licensed its Humaneered technology non-exclusively to Novartis and also in-licensed certain rights from, among others, UCSF and LICR. The Company owns 12 issued U.S. patents, with another issued U.S. patent owned jointly with a third party. It has an exclusive license to seven U.S. patents and owns 49 issued foreign patents. The Company's competitors include pharmaceutical companies, biotechnology companies, academic institutions, and other research organizations. The Company also competes with Valneva, MedImmune, Micromet along with Nycomed among others.

Top Ranked Articles about KaloBios Pharmaceuticals Inc

KaloBios Comments on Recent Scientific Publication Reporting Significantly Higher Risk of Death Associated With Chagas Infection
KaloBios to Host Company Overview Webinar on May 10
Benznidazole on Track in Progress to IND and NDA Submissions
KaloBios to Participate in Inaugural U.S. Chagas Conference

BRISBANE, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will be a speaker and panelist during the International Society for Neglected Tropical Diseases (ISNTD) Chagas conference.
ISNTD Chagas will take place on Thursday, April 6, 2017, at the Kimpton Hotel Palomar in Washington, D.C. Dr. Durrant will join Jeffrey Moe, PhD, of the Duke Global Health Institute, Anne Marie Finley of the Biotech Policy Group, and Cecilia Inés Centurión of the Chagas Disease Alliance in a session to discuss how public policy can support the development of medicines for neglected tropical diseases. “Chagas is a neglected tropical disease in the U.S. affecting approximately 300,000 underserved people, and the inaugural ISNTD Chagas conference will bring together experts and stakeholders from across the spectrum in a groundbreaking gathering in our nation’s capital,” said Dr. Durrant. “Chagas needs more attention, and with the necessary ingredients of dedicated stakeholders, enlightened public policy and patient care including approved medicines, we can hopefully make a difference. We look forward to building collaborative dialogue and understanding to improve the foundation from which to help these neglected patients.” ISNTD Chagas aims to bring together the Chagas R&D community, patient advocates, civic groups, and policymakers to further efforts to combat this neglected global health issue. For more information about the conference, please visit www.isntdchagas.com. About KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. (KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT:

Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
[email protected]

Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
[email protected]

Read more...
KaloBios Receives M&A Advisor 2017 Turnaround Award
BRISBANE, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that it has been named an M&A Advisor Turnaround Award winner for Chapter 11 Reorganization of the Year.
KaloBios received the award in the $10 million to $25 million company size category for its work to successfully emerge from Chapter 11 bankruptcy on June 30, 2016.“This award highlights our ability to execute in challenging circumstances to reach our goals and ultimately transform KaloBios,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We are grateful for the recognition of our very talented team’s efforts.”The award was presented at M&A Advisor’s 11th Annual Distressed Investing Summit. For more information on the conference and the award, please visit: http://www.cvent.com/events/2017-distressed-investing-summit-featuring-11th-annual-turnaround-awards/event-summary-4a15eb768f714edd8170809430c0a745.aspx.About KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. (KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT:

Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
[email protected]

Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
[email protected]

Read more...
KaloBios Receives $5.5M in New Financing From Existing Investors

BRISBANE, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that it has received additional proceeds of approximately $5.5 million from existing investors through an amendment to its term loan facility. Aside from the increase in the amount extended, the term loan facility remains unchanged.
The amendment brings the total principal amount of the loan from the lenders to $9.2 million. The proceeds will provide additional working capital to the company and support the ongoing development of benznidazole for potential U.S. approval to treat Chagas disease, a neglected tropical disease, and lenzilumab for chronic myelomonocytic leukemia (CMML), a rare pediatric disease, as well as current partnering efforts with ifabotuzumab. “We appreciate the continued support of our key investors as we remain on track in our development of benznidazole and lenzilumab,” said Cameron Durrant, MD, KaloBios chairman and CEO. “We will continue to execute on our strategic priorities to generate value for all of our stakeholders.” About KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. (KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially juvenile myelomonocytic leukemia, or JMML. For more information, visit www.kalobios.com. Forward-Looking Statements This release contains forward-looking statements that are intended to be subject to protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals,"  "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements related to expectations regarding benznidazole and lenzilumab and the Company's efforts to pursue partnering opportunities for ifabotuzumab. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, our lack of profitability and the need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; our ability to successfully and timely complete clinical trials for our drug candidates in clinical development; our ability to obtain the necessary U.S. and international regulatory approvals for our drug candidates and to qualify for or benefit from various regulatory incentives; the scope and validity of intellectual property and other competitive protection for our drug candidates; our ability to identify, in-license and acquire additional product candidates or to form partnerships for the sale, licensing, collaborative development or marketing of our existing product candidates; our ability to maintain or engage third-party manufacturers to manufacture, supply, store and distribute supplies of our drug candidates for our clinical trials; the success of any product; and the various risks and uncertainties described in the "Risk Factors" and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
CONTACT:

Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
[email protected]

Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
[email protected]

Read more...
KaloBios to Present at 29th Annual ROTH Conference

BRISBANE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 29th Annual ROTH Conference.
The ROTH conference will be held March 12-15, 2017, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif. For more information on the conference, please visit www.roth.com/main/Page.aspx?PageID=7280. About KaloBios Pharmaceuticals, Inc. KaloBios Pharmaceuticals, Inc. (KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT:

Investors:
Mike Cole
O: 949-259-4988
C: 949-444-1341
[email protected]

Media:
Lisa Guiterman
O: 301-217-9353
C: 202-330-3431
[email protected]

Read more...

Ratios

vs
industry
vs
history
EV-to-EBIT -1.49
KBIO's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. KBIO: -1.49 )
Ranked among companies with meaningful EV-to-EBIT only.
KBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.9  Med: 0.4 Max: 0.9
Current: -1.49
-2.9
0.9
EV-to-EBITDA -1.49
KBIO's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. KBIO: -1.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
KBIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.9  Med: 0.4 Max: 0.9
Current: -1.49
-2.9
0.9
Current Ratio 0.42
KBIO's Current Ratio is ranked lower than
93% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. KBIO: 0.42 )
Ranked among companies with meaningful Current Ratio only.
KBIO' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 2.72 Max: 11.14
Current: 0.42
0.42
11.14
Quick Ratio 0.42
KBIO's Quick Ratio is ranked lower than
91% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. KBIO: 0.42 )
Ranked among companies with meaningful Quick Ratio only.
KBIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 2.72 Max: 11.14
Current: 0.42
0.42
11.14

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.80
KBIO's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. KBIO: -53.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -169.3  Med: -157.1 Max: 0
Current: -53.8
-169.3
0

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -67.11
KBIO's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. KBIO: -67.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KBIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -67.11  Med: 165.6 Max: 269.1
Current: -67.11
-67.11
269.1

More Statistics

EPS (TTM) $ -3.32
Beta4.12
Short Percentage of Float8.17%
52-Week Range $1.90 - 6.00
Shares Outstanding (Mil)14.98

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)